Patients who may be eligible to join the trial:
Are at least 18 years of age.
Have been diagnosed with low-grade serous ovarian cancer (LGSOC).
- Have a tumor with or without a KRAS mutation (KRAS+) (the investigator can test for this if KRAS status is not known).
Have disease that is progressing or a recurrence, during or following treatment with at least one type of systemic therapy (chemotherapy).
Agree to use a highly effective contraception method during the study and for a period after the trial, if of childbearing age.
Must not be candidates for a tumor debulking surgery. Those patients may be eligible after surgery.
Must not be pregnant or breastfeeding.
Patients cannot have:
Known hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or COVID-19 infection within 28 days of starting the trial.
An active skin disorder that has required systemic therapy within the past year.
History of rhabdomyolysis.
Concurrent ocular (eye) disorders, including glaucoma, retinal vein inclusion, corneal erosion, active or recurrent dermatitis, and other forms of serious ocular surface conditions.
Concurrent congestive heart failure, history of severe cardiac disease, heart attack in the past six months, arrhythmias, unstable angina, or severe obstructive pulmonary disease.
Inability to swallow oral medications or impaired GI absorption, or active inflammatory bowel disease.
